# Fed Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers

> **NCT05125575** · PHASE1 · COMPLETED · sponsor: **Joint Stock Company "Farmak"** · enrollment: 28 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
- **DRUG:** Glucophage® XR 1000 mg Prolonged Release Tablets

## Key facts

- **NCT ID:** NCT05125575
- **Lead sponsor:** Joint Stock Company "Farmak"
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-11
- **Primary completion:** 2019-01-19
- **Final completion:** 2019-01-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05125575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05125575, "Fed Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05125575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*